SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Laboratories launches generic Zyprexa in the US

28 Oct 2011 Evaluate

Dr. Reddy's Laboratories and Teva Pharmaceutical Industries have commenced the commercial launch of Olanzapine Tablets, the generic version of Eli Lilly's Zyprexa. Based on IMS sales data, annual sales of Zyprexa were approximately $3.2 billion in the United States as of September 2011.

Teva's Olanzapine tablets in 2.5 mg, 5 mg, 7.5 mg, 10 mg and 15 mg and Dr. Reddy's Olanzapina tablets in 20 mg have each been awarded a 180-day period of marketing exclusivity in the US Dr. Reddy's is supplying the 20 mg version of the product following an April 2011 commercialization, manufacture and supply agreement with Teva. In addition, as per the terms of the agreement, Dr. Reddy's will launch their 2.5 mg, 5 mg, 7.5 mg, 10 mg ,15 mg and 20 mg of Olanzapine tablets upon expiration of the 180-day exclusivity period.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1297.00 3.75 (0.29%)
11-May-2026 12:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1874.30
Dr. Reddys Lab 1297.00
Cipla 1317.60
Zydus Lifesciences 944.10
Lupin 2262.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×